---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-020614"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:50:08.875136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance

## Summary
- Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.
- Reiterated FY2022 revenue guidance of $400-$430 million.
- Cash and investments $382.0 million, up $13.9 million from Q1 2022.
- Initiated Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
- Expects Phase 2 AIWG (miricorilant) and NASH data in Q4 2022; NDA submission for relacorilant in Cushing's in H2 2023.

## SEC filing metadata
- accession: 0001628280-22-020614
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/0001628280-22-020614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/cort-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-020614
- JSON: https://secwatch.observer/filing/0001628280-22-020614.json
- Plain text: https://secwatch.observer/filing/0001628280-22-020614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.